Topical antifungals, although often effective, are being discouraged in the early treatment of seborrheic dermatitis now that ...

M&A didn’t return as hoped for in 2024. The biopharma industry is heading into the J.P. Morgan Healthcare Conference next week in a grim mood.

Many leading stocks flashed buy signals Friday as the market rebounded, including Nvidia. CEO Jensen Huang gives a key speech ...

JGBs fall in the morning Tokyo session, tracking Friday’s price declines in U.S. Treasurys. Market participants are likely to ...

BMS-986484 is under clinical development by Bristol-Myers Squibb and currently in Phase I for Non-Small Cell Lung Cancer.

Zolacabtagene autoleucel is under clinical development by Bristol-Myers Squibb and currently in Phase I for Marginal Zone B-cell Lymphoma.

Regeneron Pharmaceuticals is a strong investment with robust growth potential, fueled by FDA approvals and resilient market ...

The FDA approved subcutaneous nivolumab for solid tumors, tiselizumab for advanced gastric and GEJ cancers, and key 2024 breast cancer breakthroughs are reviewed. Experts provide perspective on ...